The Use of Cold Plasma to Facilitate CRISPR

This technology is a compact, automated cold plasma generator engineered to enable safe and efficient delivery of CRISPR-Cas9 into cells without chemical reagents. Through the use of cold plasma, cell membranes are transiently permeabilized, creating a controlled pathway for the entry of gene-editing components. This approach directly addresses critical barriers to the adoption of CRISPR by providing a delivery mechanism that is less invasive, more predictable, and broadly compatible with diverse cell types. This technology establishes a new standard for integrating cold plasma methods into genome editing workflows, supporting applications in both research and clinical environments with improved reliability, safety, and scalability.

Background: 
Delivery of CRISPR-Cas9 into cells remains one of the most significant challenges in the advancement of gene editing. Existing methods such as viral vectors, lipid nanoparticles, and electroporation each carry substantial drawbacks. Viral vectors are associated with safety risks and potential immune reactions, while lipid and chemical reagents may compromise cell viability and lead to inconsistent outcomes. Electroporation is often cost-intensive and limited in effectiveness across different cellular models. The disclosed technology provides a reagent-free solution that reduces toxicity and immunogenicity while maintaining high efficiency of cellular uptake. By combining automation with cold plasma innovation, the disclosed technology addresses delivery inefficiency, minimizes off-target effects, and offers an alternative to costly and restrictive systems currently in use.

Applications: 

• Gene editing research in academic, industrial, and clinical laboratories
• Biotechnology and pharmaceutical product development
• Personalized medicine and regenerative medicine programs
• Agricultural biotechnology and crop trait engineering
• Preclinical and clinical studies requiring efficient CRISPR delivery

Advantages: 

• Reagent-free delivery method that decreases cytotoxicity and immunogenicity
• Compact, automated system adaptable to standard laboratory environments
• Increased speed and efficiency of CRISPR-Cas9 uptake across multiple cell types
• Lower cost compared to viral or nanoparticle-based delivery methods
• Reduced off-target effects, improving overall precision of genome editing
• Scalable platform suitable for both research and clinical translation